April 2023 - Page 2 of 3 - BioMedWire (BMW)

WednesdayApr 19, 2023 2:40 pm

Allergic Reactions Caused by Gel Nail Polishes on the Rise

A survey of 742 individuals found that 16% had experienced serious reactions to gel polish. A warning on this issue was first issued in 2018 by the British Association of Dermatologists following reports of a significant increase in allergic skin reactions linked to the chemicals. Dermatologists recently brought the issue to light again, noting the steep rise in the number of individuals who develop allergies caused by gel nail polishes seeping into their skin. The warning notes that the chemicals found in these products may cause a serious, itchy rash to develop on one’s skin as well as loosen the…

TuesdayApr 18, 2023 1:21 pm

How Pharmacies Should Prepare for Future Health Care Landscape

The healthcare landscape has changed significantly, especially since the coronavirus pandemic, and will continue to do so as technology advances. The pandemic highlighted how crucial pharmacists were in keeping individuals healthy. It has also become clear that pharmacies help mold health outcomes in a number of ways. However, to successfully move forward in the industry, pharmacies will need to step it up a notch or two. They can start to do so by considering how certain changes may affect their daily operations and make the necessary adjustments. For instance, the shift toward value-based care models is important to consider as…

TuesdayApr 18, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland

BiondVax participated in the life science industry’s 17th annual Bio-Europe Spring Conference, held this year in Switzerland BiondVax was highlighted as one of the “best ideas” in a NASDAQ-published article after the completion of the conference The company’s biobetter nanosized antibody therapies promise stability at high temperatures, superior binding affinity, convenient routes of administration, and cost effective production The EBD Group’s 17th annual Bio-Europe Spring Conference was held March 20-22, 2023, in Basel, Switzerland. The conference showcased three thematic pillars - the business of biotech, therapeutic insight tracks, and ecosystem influencers. The elite European bio-tech conference featured a mix of…

MondayApr 17, 2023 1:32 pm

Biden Signs Measure to End National COVID-19 Emergency

Earlier this week, President Joseph Biden signed a bill that would end the COVID-19 national emergency with immediate effect. The national emergency was first enacted in 2020, during former President Donald Trump’s administration. Initially, the White House had announced plans to extend the national emergency as well as the public health emergency until May 11, 2023. However, GOP members in the House introduced measures to end both immediately. In a statement of administration policy, the White House stated that a sudden end to the emergency proclamations would cause uncertainty and chaos throughout the healthcare system. This is primarily because these…

FridayApr 14, 2023 11:48 am

Study Finds That Tinnitus, Hearing Loss Are Common in Cancer Survivors

New research has found that hearing issues are common among adult patients who survive cancer. The study, conducted by researchers at UC San Francisco, discovered that more than one-half of cancer survivors who underwent chemotherapy had significant hearing issues. Prior to this, it was unknown how often survivors of lung, gastrointestinal, gynecologic or breast cancer suffered tinnitus and hearing loss. Tinnitus refers to ringing in the ears. For their study, the researchers recruited 273 survivors, with an average age of 61. All individuals involved had concluded cancer treatment about five years before. The researchers discovered that roughly 35% of them…

FridayApr 14, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring

BiondVax Pharmaceuticals is a biotechnology company developing, manufacturing, and commercializing innovative NanoAb immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases Company CEO Amir Reichman recently presented at the BIO-Europe Spring conference, where he talked about BiondVax’s successful preclinical in vivo results of its innovative inhaled COVID-19 treatment and additional pipeline plans The in vivo results have shown that the company’s inhaled COVID-19 therapy, formulated using alpaca-derived nanosized antibodies (“NanoAbs”), resulted in milder and shorter illness, virtually eliminated the virus from the lungs, and prophylactically protected against illness Since he was appointed CEO in early 2021, Reichman…

ThursdayApr 13, 2023 1:45 pm

US Federal Agency Plans to Overhaul Organ Transplant Network

Last month, the U.S. government revealed its plan to overhaul the country’s organ transplant system. The system isn't meeting the needs of many patients, with about 104,000 individuals awaiting organ transplants on the list. It is said that 17 individuals die daily waiting for a transplant, with minority and/or poor patients being overlooked in favor of White and affluent individuals. For almost four decades now, the United Network for Organ Sharing (UNOS) has managed this system. The federal Health Resources and Services Administration administrator, Carole Johnson, has proposed that some of the responsibility shouldered by UNOS be entrusted to other…

ThursdayApr 13, 2023 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer

Glioblastoma (“GBM”), an aggressive and generally fatal brain cancer, has attracted attention as a significant unmet medical need because of its incurability, claiming the lives of more than 200,000 patients worldwide each year CNS Pharmaceuticals is in the middle of a potentially pivotal global Phase 2 clinical trial for its drug candidate, a novel anthracycline called Berubicin that is apparently unique in its ability to cross the blood-brain barrier to target central nervous system tumors CNS’s clinical trial sites have begun enrolling patients in the United States, France, Spain and Switzerland, with sites prepared to receive patients in Italy as…

WednesdayApr 12, 2023 3:29 pm

Study Explores Effects of MRI Scans During Cancer Treatment

Dutch scientists have found that the majority of brain cancer patients who have repeated MRI scans of their brains in follow-up visits tolerate the sessions quite well. However, if given a choice, most cancer patients would avoid gadolinium-based contrast agents (GBCAs) in cases with diagnostically equivalent results. The research team published its results in the “Journal of Neuro-Oncology” in late March. According to the team, the study findings could allow clinicians to improve the care of patients diagnosed with primary brain tumors, particularly glioma. Gliomas are a deadly type of primary brain tumor that starts growing in the brain or…

TuesdayApr 11, 2023 1:59 pm

Electronic Health Data Could Boost Chronic Disease Surveillance

Accurate and timely information plays a crucial role in maintaining public health. As the recent coronavirus pandemic showed, securing the right information as early as possible can allow for the creation of preventative and mitigation strategies. Even though the worst of the pandemic is now behind us, some lessons we learned, such as the value of transmitting electronic health records (EHR) to public health agencies, will still be significant moving forward. NYU Grossman School of Medicine’s Lorna Thorpe, PhD, and Brian Dixon, PhD, MPA, from Indiana University Richard M. Fairbanks School of Public Health and the Regenstrief Institute, will talk…